The South Korea food and drug safety ministry has authorised the use of US biotechnology company and vaccine developer Novavax Inc's (Nasdaq:NVAX) COVID-19 vaccine, Reuters news agency reported on Wednesday.
Vaccine developer SK Bioscience Co Ltd (KRX:302440) will produce the Novavax two-dose, protein-based vaccine for the country.
This vaccine has secured authorisations from European Union regulators and the World Health Organization. It has also been authorised in India, Indonesia and the Philippines.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine